Yusuf Jimoh

Mr. Yusuf Jimoh

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2024 in Chemistry Proceedings
Verified
Conference Paper
Open access
PDF file
YJYusuf Jimoh
Yusuf Jimoh
IAIdris Yunusa Abdullah
Idris Yunusa Abdullah
AHAsmau Nasiru Hamza
Asmau Nasiru Hamza
MAmaryam abdullahi
maryam abdullahi
AOAhmadu Jibril Oludare
Ahmadu Jibril Oludare
ZSZukhruf Salami
Zukhruf Salami
Malaria, a devastating disease caused by Plasmodium parasites, continues to pose a significant threat to global health, with increasing resistance to current antimalarial drugs. In this study, we employed an in silico approach to design and evaluate novel 2-pyrazoline carboxamide derivatives as potential protease inhibitors against Plasmodium falciparum. Our results show that all the designed ligands exhibit good drug-like properties, satisfying Lipinski’s rule of five, and have low toxicity profiles. Molecular docking studies revealed that five newly designed ligands (P5, P6, P7, P11, and P13) exhibit promising binding affinities and interactions with key protease enzymes involved in the hemoglobin degradation pathway, including Falcipain-2, Falcipain-3, and Plasmepsin-2 with PDB (Protein Data Bank) codes of 6JW9, 3BWK, and 1LF3, respectively. Notably, ligand P13 showed the strongest binding affinity with Falcipain-2, forming an additional hydrogen bond with CYS42, an essential residue for the enzyme’s catalytic activity. The interactions between the ligands and the enzymes suggest a competitive inhibition mechanism, with the potential to disrupt the hemoglobin degradation pathway and halt the parasite’s lifecycle. The biological implications of these findings are significant, as they suggest that these novel ligands could be effective against Plasmodium parasites, particularly in the context of increasing resistance to current antimalarial drugs. Overall, this study provides valuable insights into the potential of novel 2-pyrazoline carboxamide derivatives to serve as protease inhibitors against Plasmodium parasites, highlights their potential as a promising strategy for antimalarial drug development, and demonstrates the importance of in silico approaches in the discovery of novel therapeutics.

30 September 2024 in Journal of Drug Design and Medicinal Chemistry
Verified
Journal Article
Open access
PDF file
DAUDA GARBADAUDA GARBA
DAUDA GARBA
YJYusuf Jimoh
Yusuf Jimoh
AAAkande Amatul-Hafeez
Akande Amatul-Hafeez
HAHassan Lukman Ali
Hassan Lukman Ali
MYmuhammad shamsudeen yakubu
muhammad shamsudeen yakubu
AOAkeem Ayodele Olaiya
Akeem Ayodele Olaiya
Malaria continues to be one of the most devastating global health problems due to the high morbidity and mortality it causes in endemic regions. The search for new antimalarial targets is vital because of the increasing prevalence of drug resistance in malaria parasites. Malarial proteases constitute promising therapeutic targets as they play important roles in the parasite life cycle. The inhibition of these enzymes has pharmacological and therapeutic significance since they are involved in numerous processes, including the development, invasion, egress, and breakdown of host hemoglobin to release amino acids for parasite sustenance. In this study, in silico techniques were used to shed light on the mechanisms underlying the inhibitory effects of prenylated quercetin isolated from Globimetula oreophila on plasmepsin I and II, falciparum 2 and 3, Plasmodium falciparum calcium-dependent protein kinase 2, dihydrofolate reductase-thymidylate synthase, and serine repeat antigen 5. The test compound significantly interacts with key enzyme binding pockets through hydrogen bonds, van der Waals, and hydrophobic interactions, influencing protease specificity control. Crucial ligand features like carbonyl and hydroxyl groups were identified as essential for receptor interactions. Comparative analysis revealed the test compound's strong binding affinities with energies ranging from -6.4 Kcal/mol to -9.4 Kcal/mol, indicating competitive potential against various enzymes, particularly excelling against PfDHFR-TS, plasmepsin-I, and SERA5 compared to native ligands. This suggests the compound's ability to competitively inhibit enzyme activity by targeting co-factor binding sites, especially with specific proteases, holding promise for therapeutic applications as potent inhibitors for the prevention and treatment of malaria.

22 April 2026 in Discover Chemistry
Verified
Journal Article
Open access
PDF file
EOEnayi Onaji
Enayi Onaji
GAGrace Adaji
Grace Adaji
CAChukwunenye Christopher Azubuike
Chukwunenye Christopher Azubuike
MAMukhtar Sani Adam
Mukhtar Sani Adam
LALucky Apeh
Lucky Apeh
EOEdwin Ameh Ojila
Edwin Ameh Ojila
Triple-negative breast cancer (TNBC) is an aggressive malignancy characterized by the absence of conventional hormonal receptors, leading to intrinsic resistance to standard therapies and poor clinical outcomes. Topoisomerase I (TOP1) and Topoisomerase II alpha (TOP2A), essential enzymes for DNA replication and transcription, have emerged as promising co-targets to overcome this therapeutic resistance. This study employed an integrated in-silico pipeline to discover novel dual-targeting inhibitors against both TOP1 and TOP2A. A structure-based pharmacophore model (AAHRR_7) was developed and rigorously validated, demonstrating high predictive power. Subsequent virtual screening of a ZINC in-trial compound library identified 475 hits, which were advanced to molecular docking against the crystal structures of TOP1 (PDB: 1T8I) and TOP2A (PDB: 4FM9). This process yielded 15 top-ranked compounds with significantly superior predicted binding affinities compared to reference inhibitors. MM/GBSA refinement and systematic ADMET profiling further prioritized two in-silico candidate molecules ZINC13740825 and ZINC00586527 which exhibited robust binding free energies and favorable drug-like properties with low predicted toxicity. Quantitative structure-activity relationship (QSAR) models and Molecular Dynamics Simulation studies confirmed their potent predicted inhibitory activity and complex stability against both targets. These findings highlight the potential of these identified compounds as promising dual TOP1/TOP2A inhibitors for TNBC therapy, offering a strategic avenue to combat resistance mechanisms. Further experimental validation is warranted to translate these computational insights into therapeutic candidates.

5 January 2026 in ChemRxiv
Verified
Preprint
Open access
PDF file
YJYusuf Jimoh
Yusuf Jimoh
AAAbdullahi Ahmad
Abdullahi Ahmad
USummulkhair sani
ummulkhair sani
AHAsmau Nasiru Hamza
Asmau Nasiru Hamza
MAmaryam abdullahi
maryam abdullahi
DAUDA GARBADAUDA GARBA
DAUDA GARBA
Antibiotic resistance poses a critical global health threat, necessitating new strategies to address multidrug-resistant bacteria. This study presents the in silico design and evaluation of five novel benzimidazole derivatives (B1–B5) as dual-action inhibitors targeting both the AcrB efflux pump and NDM-1 carbapenemase two major contributors to antibiotic resistance in Gram-negative pathogens. Computational tools, including Chemdraw, Spartan14, Chimera, Autodock Vina, and Biovia Discovery Studio, were employed for molecular modeling, docking, and visualization of key molecular interactions. All compounds satisfied Lipinski’s rule of five, exhibited high predicted gastrointestinal absorption, and demonstrated favorable pharmacokinetic profiles. Toxicity assessments indicated low to moderate risk, with B4 identified as the safest candidate (LD50: 3420 mg/kg). Molecular docking revealed that B1 and B5 displayed superior binding affinities to NDM-1 (-6.9 and -7.0 kcal/mol, respectively), outperforming the native ligand, while B3 and B4 matched or exceeded the native ligand’s binding to AcrB (-11.1 and -11.0 kcal/mol). Detailed interaction analysis highlighted the importance of hydrogen bonds, pi-alkyl, and pi-pi stacking in stabilizing these complexes. These findings suggest that the designed benzimidazole derivatives hold promise as dual-target inhibitors, offering a potential pathway for developing new therapeutics to combat antibiotic resistance. Further experimental validation is recommended to confirm these computational results and advance these candidates toward clinical application.

21 November 2025 in Chemistry Proceedings
Verified
Conference Paper
Open access
PDF file
HMHASSANAH MOMOH
HASSANAH MOMOH
YJYusuf Jimoh
Yusuf Jimoh
DAUDA GARBADAUDA GARBA
DAUDA GARBA
JYJamilu Yau
Jamilu Yau
MSMohammed Ibrahim Sule
Mohammed Ibrahim Sule
YSYahaya Mohammed Sani
Yahaya Mohammed Sani
The parasitic disease malaria necessitates novel drug targets due to increasing Plasmodium falciparum resistance. The purpose of this work was to investigate the antimalarial properties of four metabolites, namely catechin (Y10), catechin-3-gallate (Y11), 4-methoxyphenyl acryl aldehyde (Y12), and 4-hydroxy-3-methoxy acryl aldehyde (Y13), derived from Tapinanthus globiferus, a traditional medicinal plant. Docking studies with important Plasmodium aspartic proteases, Plasmepsins I and II, showed good binding affinities, and Y11 showed the best binding affinity and a critical interaction with the catalytic dyad of Plm-II. The ADMET profile showed drug-likeness with low toxicity. These findings therefore position these metabolites, particularly Y11, as promising lead compounds for the development of antimalarial drugs.

2 November 2026 in Chemistry Proceedings
Verified
Conference Paper
Open access
PDF file
YJYusuf Jimoh
Yusuf Jimoh
HAHayder Raed Al-tameemi
Hayder Raed Al-tameemi
ZSZukhruf Salami
Zukhruf Salami
AAAbdullahi Ahmad
Abdullahi Ahmad
Cancer remains a leading cause of mortality in sub-Saharan Africa, with limited access to targeted therapies driving demand for affordable, novel lead compounds. Irvingia gabonensis (Aubry-Lecomte ex O’Rorke) Baill., known as ogbono or African bush mango, is a nutritional staple across West and Central Africa whose seed harbours bioactive phytochemicals. Molecular docking studies were conducted using AutoDock Vina (version 1.2.0) against three oncogenic targets: Bcl-2 (PDB: 6O0K), phosphoinositide 3-kinase gamma (PI3K-gamma; PDB: 1E8X), and the nuclear factor kappa-B p65 subunit (NF-kB p65; PDB: 2RAM). Five phytocompounds, namely ellagic acid, quercetin, kaempferol, lupeol, and beta-sitosterol, were evaluated alongside three reference drugs: venetoclax, idelalisib, and BAY 11-7082. Pharmacokinetic profiling was assessed through Lipinski, Veber, and Ghose drug-likeness filters, and ADMET properties were predicted using computational descriptors. Quercetin exhibited the highest binding affinity among phytocompounds, recording −9.1 kcal/mol against PI3K-gamma and −8.9 kcal/mol against Bcl-2, approaching reference idelalisib (−9.8 kcal/mol). Kaempferol and ellagic acid demonstrated consistent multi-target engagement across all three proteins. Four of five phytocompounds satisfied Lipinski criteria with zero or one violation. ADMET analysis revealed favourable safety profiles relative to reference drugs, with no predicted hERG inhibition or hepatotoxicity across phytocompounds. The phytocompound matrix of I. gabonensis seeds constitutes a computationally validated multi-target oncological scaffold. Quercetin and kaempferol emerge as the most promising phytocompounds for further experimental investigation. This study provides a reproducible computational framework and advances the case for repositioning an African food crop as a natural product lead in cancer drug discovery.